A new study has revealed that the antibiotic most commonly prescribed to treat bloodstream infections in dialysis patients may not always be the best choice. The study appears in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
When Staphylococcus aureus bacteria gain access to a patient''s bloodstream, the infection then becomes life threatening. Antibiotics can often cure this infection, but without any antibiotic treatment, more than 80% of patients with bloodstream infections are likely to die. But what''s the most appropriate antibiotic to use?
AdvertisementKevin Chan, MD (Fresenius Medical Care North America and Massachusetts General Hospital) and his colleagues compared the effectiveness of various antibiotics at preventing hospitalization and death from bloodstream infection. They reviewed more than 500,000 blood culture results from their chronic kidney disease database, looking for methicillin-sensitive strains of S. aureus bloodstream infection. They also identified when physicians used vancomycin or cefazolin to treat these infections. Vancomycin is often perceived as the better antibiotic because it has broad coverage against many strains of bacteria; however, other factors like the antibiotic''s killing power and tissue penetration are also important factors in selecting the best treatment.
Among the major findings:
- 56% of patients remained on vancomycin after blood culture results reported S. aureus bacteria were susceptible to cefazolin, while only 17% were treated with cefazolin.
- Cefazolin-treated patients experienced a 38% lower rate of hospitalization and death compared with vancomycin-treated patients.
- Cefazolin-treated patients also had a 48% lower rate of sepsis, which is the most serious form of bloodstream infection.
"I think the data suggest there is an opportunity to improve outcomes for patients through appropriate antibiotic selection," said Dr. Chan.
Study co-authors include H. Shaw Warren, MD, Ravi Thadhani, MD (Massachusetts General Hospital); David J.R. Steele, MD, Jeffrey L. Hymes, MD, Franklin Maddux, MD (Fresenius Medical Care North America); and Raymond Hakim, MD, PhD
Disclosures: None of the authors have ties to the manufacturers of vancomycin or cefazolin, the two antibiotics studied in this analysis. Both drugs are currently available in generic form in the United States.
The article, entitled "Prevalence and Outcomes of Antimicrobial Treatment for Staphylococcus Aureus Bloodstream Infection in Outpatients with End-Stage Renal Disease," will appear online at http://jasn.asnjournals.org/ on August 16, 2012, doi: 10.1681/ASN.2012010050.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
P How Antibiotic-Resisting Bacterial Infections may Form Demystified Brazil Beauty Market Gets a Fillip from the Booming Middle Class M